Back to search

Article

Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS <sup>G12D</sup> inhibitor MRTX1133

2023-03-23

Abstract excerpt

Mutations in KRAS are common drivers of human cancers and are often those with the poorest overall prognosis for patients. A recently developed compound, MRTX1133, has shown promise in inhibiting the activity of KRAS G12D mutant proteins, one of the main drivers in pancreatic cancer. To better understand the mechanism of action of this compound I performed both proteomics and metabolomics on four KRAS G12D mutan...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e3f4f1e1-7f12-5acf-8f96-12846c8cc193
DOI
10.1101/2023.03.23.533981
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS <sup>G12D</sup> inhibitor MRTX1133DOI 10.1101/2023.03.23.533981
Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRASG12D Inhibitor MRTX1133.Semantic proximity
Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity
Screening Metabolic Biomarkers in KRAS Mutated Mouse Acinar and Human Pancreatic Cancer Cells via Single-Cell Mass Spectrometry.Semantic proximity
Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.Semantic proximity
Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis.Semantic proximity
Pathway-selective strategies reveal specific PI3K–mTOR inhibitors as key partners in KRAS G12D-targeted therapySemantic proximity
Large pan-cancer cell screen coupled to (phospho-)proteomics underscores high-dose vitamin C as a potent anti-cancer agentSemantic proximity
Single Cell Proteomics Using a Trapped Ion Mobility Time-of-Flight Mass Spectrometer Provides Insight into the Post-translational Modification Landscape of Individual Human CellsSemantic proximity
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.Semantic proximity
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cellsSemantic proximity
Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutationSemantic proximity
Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic DataSemantic proximity
Select a neighboring publication to make it the new centre.